公开(公告)号：WO9955385A3

公开(公告)日：2000-03-16

申请号：PCT/DE9901237

申请日：1999-04-27

Applicant: BERGTER WOLFGANG ,  BERGTER INGRID CORINA

Inventor： BERGTER WOLFGANG ,  BERGTER INGRID-CORINA

IPC: A61K51/10 ,  A61K51/08

CPC classification number: A61K51/1006

Abstract: The invention relates to radioimmunoconjugates for the in-vivo elimination of virus-replicating cells in patients infected with the hepatitis C virus (HCV). The inventive radioimmunoconjugates are characterized in that they contain, as immunologically active components, (a) a monoclonal antibody or the antigen-binding fragment thereof directed against a viral or virus-induced antigen expressed on the plasma membrane of HCV-infected cells; (b) a receptor molecule or a fragment of the receptor molecule with an affinity to an epitope of the surface glycoproteins E1 and/or E2, or; C) a fragment of the receptor molecule, said fragment being modified by random or selective mutagenesis, with an affinity to an epitope of the surface glycoproteins E1 and/or E2. In addition, the radioimmunoconjugates are characterized in that they contain, as radioactive components, a radioisotope having a shorter half-life and a lower range, for example, d) J, or e) P, or f) Y, or g) Sr. The radioimmunoconjugates are contained together with pharmaceutical supporting materials and/or auxiliary agents.

Abstract translation: 用于在HCV感染患者的病毒复制的细胞的体内消除放射性免疫缀合物，其特征在于它BZY作为免疫学活性组分a）的单克隆抗体，其抗原结合片段以一个对病毒或质膜HCV感染的细胞中表达的病毒诱导的 抗原，或b）一个RezeltormolekülBZV具有亲和力的受体分子的表面糖蛋白E1和/或E2，或一个表位的片段c）中通过用表面糖蛋白E1和/或E2的einemm表位亲和力受体分子的随机或靶向诱变片段的修饰 并且它们<90> Y，或者含有克）<89>以Sr为放射性组分是具有短的半衰期和短程放射性同位素，例如，d）<131> J或E）<32> P，或f）。 与药用载体和/或赋形剂包括沿。

公开(公告)号：WO9945969A2

公开(公告)日：1999-09-16

申请号：PCT/DE9900598

申请日：1999-03-05

Applicant: BERGTER WOLFGANG ,  BERGTER INGRID CORINA

Inventor： BERGTER WOLFGANG ,  BERGTER INGRID-CORINA

IPC: A61K51/00 ,  A61K39/395 ,  A61K51/10

CPC classification number: A61K51/1039

Abstract: The invention relates to a radioimmuno-pharmacon for treating the HIV-1 infection. The disadvantages of standard HIV therapies are that the medicaments currently used must be taken daily in large quantities (approx. 30 tablets per day), in accordance with a strict timetable and for the rest of the patient's life, and that they cause numerous side effects. In addition, conventional medicaments only reduce the replication of the virus. They do not eliminate the host cells infected with HIV and therefore do not cure the HIV infection. The inventive radioimmuno-pharmacon consists of a monoclonal antibody and a radionuclide for eliminating HIV-replicating cells in patients infected with HIV-1 in vivo after the virus burden has been reduced with an antiretroviral therapy and optionally, with the added protection of a host cell transplantation and with medicamentous protection of thyroid activity. According to the invention, this radioimmuno-pharmacon is administered to the HIV-1-infected patient intravenously, once or in several cycles. It targets and inflicts lasting damage on the host cells in order to eliminate as near to all of them as possible. The aim is to heal the HIV infection or at least slow down the progression of the disease.

Abstract translation: 在HIV-标准疗法的缺点包括目前大量使用对生命的药品日常的事实（每天约30粒），应采取按照严格的时间表，并有许多副作用。 在另一方面，常规药物只能导致病毒复制的减少。 艾滋病毒感染的宿主细胞没有消除，因此，HIV感染没有痊愈。 本专利申请描述了一种放射免疫测定法药物组成的单克隆抗体，并在体内消除HIV-复制的细胞中HIV-1感染的患者通过用抗逆转录病毒治疗与干细胞和medikamentösem的保护，减少病毒载量以及任选的放射性核素 保护甲状腺的功能。 此放射免疫测定药物应一次或在几个循环HIV-1感染的患者静脉内施用并且具体HIV复制的宿主细胞，因为所有的宿主细胞被消除，从而长期损害。 我们的目标是治愈HIV感染，或至少疾病进展的延迟。